Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideyuki Akaza

Showing results (1-10 of 334) with videos related to

Pageof 34
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 10, 2016
[Urological Cancer 2015]Hideyuki Akaza
The Canadian Journal of Urology|March 23, 2005
Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?Hideyuki Akaza
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 30, 2012
[Genitourinary cancer, biomarker; current progress]Hideyuki Akaza
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 8, 2013
[Genitourinary tumor]Hideyuki Akaza
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 25, 2018
[Genitourinary Tumor Four Questions about Bladder Cancer]Hideyuki Akaza
Japanese Journal of Clinical Oncology|May 18, 2021
Surviving cancer in Asia: cross-boundary cancer studies, University of TokyoHideyuki Akaza
Japanese Journal of Clinical Oncology|May 18, 2021
Lecture No. 2 Is UHC for cancer in Asia an achievable goal?Hideyuki Akaza
Japanese Journal of Clinical Oncology|February 3, 2016
What is the Asian Consensus Statement on NCCN clinical practice guidelines in oncology (NCCN-ACS)?Hideyuki Akaza
Cancer Biology & Medicine|December 19, 2013
Asian trends in primary androgen depletion therapy on prostate cancerHideyuki Akaza
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 6, 2017
[Four Questions about Prostate Cancer in Japan]Hideyuki Akaza
Pageof 34

Showing results (1-10 of 334) with videos related to

Sort By:
Pageof 34
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 10, 2016
[Urological Cancer 2015]Hideyuki Akaza
The Canadian Journal of Urology|March 23, 2005
Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?Hideyuki Akaza
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 30, 2012
[Genitourinary cancer, biomarker; current progress]Hideyuki Akaza
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 8, 2013
[Genitourinary tumor]Hideyuki Akaza
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 25, 2018
[Genitourinary Tumor Four Questions about Bladder Cancer]Hideyuki Akaza
Japanese Journal of Clinical Oncology|May 18, 2021
Surviving cancer in Asia: cross-boundary cancer studies, University of TokyoHideyuki Akaza
Japanese Journal of Clinical Oncology|May 18, 2021
Lecture No. 2 Is UHC for cancer in Asia an achievable goal?Hideyuki Akaza
Japanese Journal of Clinical Oncology|February 3, 2016
What is the Asian Consensus Statement on NCCN clinical practice guidelines in oncology (NCCN-ACS)?Hideyuki Akaza
Cancer Biology & Medicine|December 19, 2013
Asian trends in primary androgen depletion therapy on prostate cancerHideyuki Akaza
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 6, 2017
[Four Questions about Prostate Cancer in Japan]Hideyuki Akaza
Pageof 34